Background: Most immunogenetic studies restrict the location of the susceptibility gene for psoriasis to the HLA-C locus. Objective: The present study evaluates the amino acid sequences of the HLA-C binding groove associated with the disease in a restricted population of Italian descent: Pavia, Northern Italy. Method: Forty patients, affected by psoriasis, underwent genomic analysis of exons 2 and 3 of the HLA-C gene by means of the PCR-SSP technique. Results: The HLA-C*0602 gene frequency was significantly higher in patients with respect to 122 sex-, age- and ethnically matched controls (25 vs. 8.6%, χ2 = 14.65, p = 0.000129). This frequency rose to 39.5% in patients with a family history positive for psoriasis. In particular, 4 amino acid substitutions were shown to be crucial for the predisposition to the disease, namely Ala 73 and Asn 77 (located in the C pocket of the antigen binding groove), Lys 80 in the F pocket and Asp 90 in the outer loop of the molecule. This peculiar motif, entirely located in the α1-domain of the HLA-C molecule, was characteristic of psoriatic patients being present in 77.5% of the cases against the 50.82% of controls (χ2 = 8.77; p = 0.0031). Homozygosity for the amino acids considered at these residues was found in 15% of patients and in 0% of controls (χ2 = 20.74, p = 0.0000053). Conclusion: The most important results emerging from this study indicate that Ala 73, Asn 77, Lys 80 and Asp 90 together form a motif restricted to few pathogenic peptides to be studied in the near future.

Keywords:
Psoriasis, HLA-C sequence motif, α1-Domain
1.
Greaves MW, Weinstein GD: Treatment of psoriasis. N Engl J Med 1995;332:581–588.
2.
Elder JT, Nair RP, Voorhees JJ: Epidemiology and the genetics of psoriasis. J Invest Dermatol 1994;102:24S–28S.
3.
Trowsdale J, Ragoussis J, Champbell RD: Map of the human MHC. Immunol Today 1991;12:443–446.
4.
Ikaheimo I, Silvennoinen-Kassinen S, Karvonen J, Jarvinen T, Tilikainen A: Immunogenetic profile of psoriasis vulgaris: Association with haplotypes A2, B13, Cw6, DR7, DQA1*0201 and A1, B17, Cw6, DR7, DQA1*0201. Arch Dermatol Res 1996;288:63–67.
5.
Russel TJ, Schultes LM, Kuban DJ: Histocompatibility (HLA) antigens associated with psoriasis. N Engl J Med 1972;287:738–740.
6.
Schmitt-Egenolf M, Boehncke WH, Stander M, Eiermann TH: Oligonucleotide typing reveals association of type I psoriasis with the HLA-DRB1*0701/2, DQA1*0201, DQB1*0303 extended haplotype. J Invest Dermatol 1993;100:749–752.
7.
Schmitt-Egenolf, Eiermann TH, Boehncke WH, Stander M, Sterry W: Familial juvenile onset psoriasis is associated with the human leukocyte antigen (HLA) Class I side of the extended haplotype Cw6-B57-DRB1*0701-DQA1*0201-DQB1*0303: A population and family-based study. J Invest Dermatol 1996;106:711–714.
8.
Ikaheimo I, Silvennoinen-Kassinen S, Karvonen J, Tilikainen A: Alanine at position 73 of HLA-C is associated with psoriasis vulgaris in Finland. Br J Dermatol 1994;131:257–259.
9.
Olerup O, Zetterquist H: HLA-DR typing in clinical practice including donor recipient matching in cadaveric transplantations. Tissue Antigens 1992;39:225–235.
10.
Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucl Acids Res 1988;16:1215.
11.
Mallon E, Bunce M, Wojnarowska F, Welsh K: HLA-CW*0602 is a susceptibility factor in type I psoriasis, and evidence ALA-73 is increased in male type I psoriatics. J Invest Dermatol 1997;109:183–186.
12.
Trembath RC, Clough RL, Rosbotham JL, Jones AB, Camp RD, Frodsham A, Browne J, Barber R, Terwilliger J, Lathrop GM, Barker JN: Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet 1997;6:813–820.
13.
Jenisch S, Henseler T, Nair RP, Guo SW, Westphal E, Stuart P, Kronke M, Voorhees JJ, Christophers E, Elder JT: Linkage analysis of human leukocyte antigen (HLA) markers in familial psoriasis: Strong disequilibrium effects provide evidence for a major determinant in the HLA-B/-C region. Am J Hum Genet 1998;63:191–199.
14.
Leder RO, Mansbridge JN, Hallmayer J, Hodge SE: Familial psoriasis and HLA-B: Unambiguous support for linkage in 97 published families. Hum Hered 1998;48:198–211.
15.
Garrett TP, Saper MA, Bjorkman PJ, Strominger JL, Wiley DC: Specificity pockets for the side chains of peptide antigens in HLA-Aw68. Nature 1989;342:692–696.
16.
Saper MA, Bjorkman PJ, Wiley DC: Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 Å resolution. J Mol Biol 1991;219:277–319.
17.
Matsumura M, Fremont DH, Peterson PA, Wilson IA: Emerging principles for the recognition of peptide antigens by MHC class I molecules. Science 1992;257:927–934.
18.
Chelvanayagam G: A roadmap for HLA-A, HLA-B, and HLA-C peptide binding specificities. Immunogenetics 1996;45:15–26.
19.
Bjorkman PJ, Saper MA, Samraoui B, Bennet WS, Strominger JL, Wiley DC: The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 1987;329:512–518.
20.
Bjorkman PJ, Saper MA, Samraoui B, Bennet WS, Strominger JL, Wiley DC: Structure of the human class I histocompatibility antigen, HLA-A2. Nature 1987;329:506–512.
21.
Mandelboim O, Reyburn HT, Vales-Gomez M, Pazmany L, Colonna M, Borsellino G, Strominger JL: Protection from lysis by natural killer cells of group 1 and 2 specificity is mediated by residue 80 in human histocompatibility complex molecules. J Exp Med 1996;184:913–922.
22.
Hammer J, Bono E, Gallazzi F, Belunis C, Nagy Z, Sinigaglia F: Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning. J Exp Med 1994;180:2353–2358.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.